TSUNO-GROUP
31.1.2024 08:16:27 CET | Business Wire | Press release
Tsuno Group Co., Ltd., headquartered in Katsuragi-cho, Ito-gun, Wakayama, and led by President: Fumi Tsuno and Matsumoto Trading Co., Ltd., headquartered in Chuo-ku, Tokyo, with CEO Shunsuke Matsumoto have successfully developed a new sunscreen formulation with Ferulic Acid. Ferulic Acid is a rare natural plant-derived UV absorber that has been difficult in stability and solubility at the high concentrations of ferulic acid.
For ferulic acid
Tsuno Group was the first in the world to successfully produce large amounts of ferulic acid, a polyphenol, from rice bran. Ferulic acid possesses strong antioxidant properties and has been recognized for its potential to prevent Alzheimer's disease, diabetes mellitus, and high cholesterol. It can also be used as a raw material for producing natural vanillin, a vanilla flavoring. In cosmetics, it inhibits melanin production by blocking tyrosinase activity and has anti-inflammatory, antimicrobial, and antioxidant properties. Therefore, it has been used as an active ingredient in a variety of cosmetic products.
“We, as a leading company in rice & bran chemistry in the world, have been developing a number of functional products with tremendous efforts through accumulating technologies, have also researched their safe levels and effects to be well accepted in pharma, food, feed and cosmetic industries. Now we have launched a technology of using ferulic acid from rice bran as a natural antioxidant and UV absorber, which is the first innovation ever in the world. We are confident that you shall discover this product as unique and impactful to contribute not only to the human health and beauty but the circular economy for the world.” —— Fumi Tsuno, President of Tsuno Group Co., Ltd.
UV absorption effect of ferulic acid
Ethylhexyl methoxycinnamate (EHMC), a petrochemical UV filter, is most widely used in sunscreen applications. However, recent studies have shown its negative impact on the aquatic environment, including coral bleaching. Ferulic acid, a naturally derived sunscreen ingredient from rice, absorbs UV rays in a similar range of the spectrum as octyl methoxycinnamate (OMC). This promising characteristic makes it a potential eco-friendly alternative to EHMC. Amidst growing global concerns about environmental sustainability, ferulic acid's potential as a natural and effective sunscreen ingredient is likely to gain increased recognition. It holds significant potential for application in a wide range of cosmetic products throughout Japan.
Development of high stability formulation of UV-care products with high concentration of Ferulic Acid
Gaining recognition for its UV-absorbing properties, ferulic acid, a rare natural plant-derived ingredient, presents challenges in solubility and stability at the high concentrations for sunscreen formulations. To overcome these hurdles, Matsumoto Trading has dedicated research and development, pioneering an innovative technology utilizing a high concentration of ferulic acid in a solid stick formulation. This novel formulation has been developed with SPF50+ and PA++ (in vitro) containing only ferulic acid, a natural UV absorber extracted from rice bran. This unique formulation eliminates the need for other commonly used UV protective ingredients, while maintaining high sun protection effectiveness. Patent pending.
About Tsuno Rice Fine Chemicals Co., Ltd.
Tsuno Rice Fine Chemicals manufactures various ingredients from by-products generated in the process of refining rice bran oil, and they can be used for pharmaceutical, cosmetic, functional foods, food additives, feedstock, and industrial chemicals. In addition, we are also engaged in the manufacture of cosmetics under our own brand that incorporate these ingredients.
Business Profile of Tsuno Group Co., Ltd.
We are promoting the advanced and effective use of rice bran, a symbol of health and beauty that has been popular since ancient times. We are developing three businesses: the Rice Bran Oil Production Business, the Fine Chemicals Business, and the Oleo Chemical Business.
Established: February 1, 1947
Representative Director and President Fumi Tsuno
URL : https://www.tsuno.co.jp/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240130923907/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom